 | Info
Sheets |
| | | | | | | | | | | | | | |
 | Out-
side |
| | |
|
| | |
| |
Result : Searchterm 'Phospholipid' found in 1 term [ ] and 7 definitions [ ])
| | 1 - 5 (of 8) nextResult Pages : [1] [2] | |  | | |
 |
US Resources |
|
| | | | | | | |  |
| AI-700 |   |
| |
|
From Acusphere Inc
AI-700 is an US contrast agent, usable for myocardial perfusion undergoing regulatory FDA approval. The synthetic polymers used in AI-700 do not break during the ultrasound imaging procedure. The used perfluorocarbon filling gas is less soluble in water and therefore has the propensity to stay inside the contrast agent particles. As a result, a higher concentration of gas is delivered to the myocardium over a longer period of time, thereby enabling AI-700 to target the broader application of myocardial perfusion assessment.
AI-700 is a dry powder consisting of small, porous microparticles filled with perfluoropropane. These microparticles are made of a synthetic biodegradable polymer, called poly (D, L-lactide co-glycolide), or PLGA, that has been used in other drug delivery systems approved by the FDA.
The composition and structure of the phospholipid containing microparticles and the properties of the perfluorocarbon gas slow the rate at which the gas dissolves and prevent the microparticles from being quickly broken down. The powder is to suspend in sterile water and injected by a single intravenous injection prior to ultrasound imaging.
In June 2004, Acusphere entered into a Collaboration, License and Supply Agreement with Nycomed Danmark APS for the European development and marketing rights to Acusphere’s lead product candidate AI-700.
Nycomed will be responsible for sales, marketing and the regulatory submissions required for marketing throughout its sales territory, which includes the member states of the European Union, as well as Russia/CIS and the Baltic States.
|
| Drug Information and Specification: |
| RESEARCH NAME |
AI 700 |
| DEVELOPER |
Acusphere, Inc.
|
INDICATION -
DEVELOPMENT STAGE |
myocardial perfusion |
| APPLICATION |
Intravenous injection |
| TYPE |
Microbubble |
| SHELL |
Poly-L-lactide co glycolide |
| CHARGE |
Negative |
| GAS |
Perfluorocarbon |
| MICROBUBBLE SIZE |
- |
| PREPARATION |
Reconstitute with water |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
|
|
| | | | •• There are 3 news about 'AI-700'. | | | |
 Further Reading: |
Basics:
|
|
News & More:
| | | | |
| |
|
US Resources |
|
| | | | | |
|
| |
| BR14 | |
| |
|
From Bracco Research SA, Geneva, Switzerland,
BR14 is a new experimental ultrasound contrast agent, consisting of bubbles containing a high molecular weight filling gas enclosed by a flexible phospholipid monolayer shell a few nanometers thick.
This agent shows significant non-linear scattering and agent modification even at low insonation pressures, the detection pulses used did not destroy the contrast bubbles. The results obtained with HPD before the release burst show that the BR14 bubbles are efficient scatterers that can be modified and, thus, detected by low power insonation.
|
| Drug Information and Specification: |
| RESEARCH NAME |
BR14 |
| DEVELOPER |
Bracco Diagnostics, Inc.
|
| DEVELOPMENT STAGE |
Preclinical |
| APPLICATION |
- |
| TYPE |
Microbubble |
| SHELL |
- |
| CHARGE |
Negative |
| GAS |
Perfluorobutane |
| MICROBUBBLE SIZE |
Mean size 3µm, 95% < 10µm |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
|
|
| | | |
| Further Reading: |
Basics:
|
|
News & More:
| | | |
| | |
| BY 963 | |
| |
|
By Byk-Gulden (now Altana);
The transpulmonary echo contrast agent under development, BY 963, promises to be an excellent ultrasound contrast agent for the noninvasive assessment of left ventricular function. Intravenous administration of BY 963 phospholipid microbubbles improves the reproducibility of e.g. quantitative analysis.
|
| | | |
| Further Reading: |
Basics:
|
| | |
| |
|
| |
| Coherent Contrast Imaging | |
| |
|
(CCI) A major limitation of the use of ultrasound contrast agents is the problem that signals from the microbubbles are mixed with those from tissue, so that the distribution of the microbubbles is not optimally displayed either in Doppler or gray scale.
Coherent contrast imaging is a high frame rate implementation of inverting the phase of alternate sound pulses and summing the resulting echoes. The symmetrical signals from linear reflectors are cancelled leaving those from non-linear scatterers, with the advantage that the cancellation is performed without the need to transmit two pulses per image line so that bubble destruction is minimized. Coherent contrast imaging yields best results in the vascular phase of phospholipid microbubbles (such as Definity and SonoVue).
See also Coherence.
|
| | | |
| Further Reading: |
News & More:
|
| | |
| |
|
|
US Resources |
|
| | | | | | | 1 - 5 (of 8) nextResult Pages : [1] [2] |
| |
|
| |
 | Look
Ups |
| |
bottom
(.pdf)
Random Page
top